Lung Cancer Dispatch
Follow
Find tag "amrubicin"
4.4K views | +0 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Amrubicin and Cisplatin Inferior to Irinotecan Regimen for Small-Cell Lung Cancer

Amrubicin and Cisplatin Inferior to Irinotecan Regimen for Small-Cell Lung Cancer | Lung Cancer Dispatch | Scoop.it

"A combination of amrubicin and cisplatin was inferior to irinotecan and cisplatin in chemotherapy-naïve patients with extensive disease small-cell lung cancer (SCLC) in a phase III trial conducted in Japan. The irinotecan regimen remains the standard treatment for these patients in that country.


"SCLC accounts for 13% of all new cases of lung cancer, and more than half of those patients present with extensive disease. Though SCLC can be very sensitive to chemotherapy, authors of the new study wrote that “rapid emergence of clinical drug resistance has resulted in poor prognosis, with almost all such patients dead with 2 years of initial diagnosis.” Investigators led by Miyako Satouchi, MD, PhD, of the Hyogo Cancer Center in Akashi, Japan, tested the amrubicin and cisplatin combination against irinotecan and cisplatin in 284 patients; results were published online ahead of print on March 17 in the Journal of Clinical Oncology."

Cancer Commons's insight:

Cancer Network  |  Apr 23, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Combined Calsed and S-1 May be Effective Second-Line Treatment for Lung Cancer without EGFR Mutations

While new treatments for non-small cell lung cancer (NSCLC) such as tyrosine kinase inhibitors (TKIs) and Alimta (pemetrexed) are effective second-line treatments for patients whose tumors carry mutations in the EGFR gene, they are less effective for patients without such mutations. Twenty-six patients with inoperable, previously treated NSCLC received treatment with amrubicin (Calsed) and S-1 and experienced higher treatment response rates, longer periods without cancer progression, and longer overall survival than has been reported with single-agent chemotherapy. The beneficial effects were independent of cancer subtype, suggesting that combined Calsed and S-1 may be an effective second-line treatment for NSCLC without EGFR mutation.


Research paper: http://link.springer.com/article/10.1007/s00280-012-2061-1/fulltext.html

Cancer Commons's insight:

Cancer Chemotherapy and Pharmacology | Jan 18, 2013

more...
No comment yet.